TurboHawk Helps Drive Q4 Peripheral Vascular Sales Growth At ev3
This article was originally published in The Gray Sheet
Executive SummaryDevice maker ev3's peripheral vascular sales advanced 8% to $73.7 million in the fourth quarter, driven by the new TurboHawk plaque excision system
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.